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Multi-drug resistance, inappropriate initial
antibiotic therapy and mortality in Gram-negative
severe sepsis and septic shock: a retrospective
cohort study
Marya D Zilberberg1,2*, Andrew F Shorr3, Scott T Micek4, Cristina Vazquez-Guillamet5 and Marin H Kollef6

Abstract
Introduction: The impact of in vitro resistance on initially appropriate antibiotic therapy (IAAT) remains unclear. We
elucidated the relationship between non-IAAT and mortality, and between IAAT and multi-drug resistance (MDR) in
sepsis due to Gram-negative bacteremia (GNS).
Methods: We conducted a single-center retrospective cohort study of adult intensive care unit patients with
bacteremia and severe sepsis/septic shock caused by a gram-negative (GN) organism. We identified the following
MDR pathogens: MDR P. aeruginosa, extended spectrum beta-lactamase and carbapenemase-producing organisms.
IAAT was defined as exposure within 24 hours of infection onset to antibiotics active against identified pathogens
based on in vitro susceptibility testing. We derived logistic regression models to examine a) predictors of hospital
mortality and b) impact of MDR on non-IAAT. Proportions are presented for categorical variables, and median values
with interquartile ranges (IQR) for continuous.
Results: Out of 1,064 patients with GNS, 351 (29.2%) did not survive hospitalization. Non-survivors were older
(66.5 (55, 73.5) versus 63 (53, 72) years, P = 0.036), sicker (Acute Physiology and Chronic Health Evaluation II (19 (15, 25)
versus 16 (12, 19), P <0.001), and more likely to be on pressors (odds ratio (OR) 2.79, 95% confidence interval (CI) 2.12
to 3.68), mechanically ventilated (OR 3.06, 95% CI 2.29 to 4.10) have MDR (10.0% versus 4.0%, P <0.001) and receive
non-IAAT (43.4% versus 14.6%, P <0.001). In a logistic regression model, non-IAAT was an independent predictor of
hospital mortality (adjusted OR 3.87, 95% CI 2.77 to 5.41). In a separate model, MDR was strongly associated with the
receipt of non-IAAT (adjusted OR 13.05, 95% CI 7.00 to 24.31).
Conclusions: MDR, an important determinant of non-IAAT, is associated with a three-fold increase in the risk of hospital
mortality. Given the paucity of therapies to cover GN MDRs, prevention and development of new agents are critical.

Introduction
Antimicrobial resistance is a growing challenge in the care
of critically ill patients, among whom the burden of infection remains high. Escalating rates of antibiotic resistance
add substantially to the morbidity, mortality, and cost
related to infection in the ICU [1]. Traditionally, most
efforts to understand issues of resistance and ICU outcomes have addressed Gram-positive organisms, such as
methicillin-resistant Staphylococcus aureus [2,3]. However,
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in the United States, alarming trends in resistance are now
also reported for a number of Gram-negative pathogens.
For example, extended-spectrum beta-lactamase (ESBL)
organisms are now endemic in many ICUs, and 15 to 20%
of all Pseudomonas aeruginosa isolates from serious infections are categorized as multidrug resistant (MDR)
because of reduced in vitro susceptibility to three or more
classes of antibiotics [4-6]. Of even more concern are
pathogens for which clinicians have few antibiotic options,
namely Acinetobacter baumanii and carbepenemaseproducing Enterobacteriaceae (CPE) [4-6]. In the case
of these Gram-negative organisms, studies also point
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to an association between resistance and both clinical
and economic outcomes [1].
The mechanism for poor outcomes with resistant Gramnegative organisms is not completely clear. In general, these
bacteria are not believed to be inherently more virulent
than similar susceptible species. Resistance and its rapid
evolution, however, make efforts to insure initially appropriate antibiotic therapy (IAAT) more difficult, and IAAT is
a key determinant of outcome in severe infection [7-10].
IAAT has consistently been shown to reduce mortality rates
in severe sepsis and septic shock, and the Surviving Sepsis
Campaign Guidelines strongly support initiatives to guarantee that patients receive timely antibiotic treatment [11-16].
However, it remains unclear what proportion of IAAT is
driven by in vitro resistance. Appreciating this relationship
may facilitate efforts to improve outcomes by helping clinicians determine how to apply newer diagnostic modalities
and therapeutic options.
We sought to confirm the importance of IAAT in severe
sepsis and septic shock due to Gram-negative bacteria and
to estimate the impact of initially inappropriate antibiotic
therapy (non-IAAT) on mortality in these syndromes.
More importantly, we aimed to identify variables associated with IAAT and to elucidate the relationship between
IAAT and in vitro antimicrobial resistance. To accomplish
this we conducted a large retrospective analysis of subjects with severe sepsis or septic shock and Gram-negative
bacteremia.

Materials and methods
Study design and ethical standards

We conducted a single-center retrospective cohort study
from January 2008 to December 2012. Barnes-Jewish Hospital is a 1,200-bed urban academic medical center located
in St. Louis, MO, USA. The study was approved by the
Washington University School of Medicine Human Studies
Committee and informed consent was waived since the
data collection was retrospective without any patientidentifying information. The study was performed in
accordance with the ethical standards of the 1964
Declaration of Helsinki and its later amendments.
Study cohort

All consecutive adult ICU patients between January
2008 and December 2012 were included if: they had a
positive blood culture for a Gram-negative organism;
and there was an International Classification of Diseases,
Version 9, Clinical Modification (ICD-9-CM) code corresponding to an acute organ dysfunction [17]. Only the
first episode of sepsis was included.
Definitions

To be included in the analysis, patients had to meet criteria for severe sepsis based on discharge ICD-9-CM
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codes for acute organ dysfunction [17]. Patients were
classified as having septic shock if vasopressors (norepinephrine, dopamine, epinephrine, phenylephrine, or
vasopressin) were initiated within 24 hours of the blood
culture collection date and time. Antimicrobial treatment was deemed IAAT if the initially prescribed antibiotic regimen was active against the identified pathogen
based on in vitro susceptibility testing and was administered within 24 hours following blood culture collection.
Combination therapy was not required to be considered
IAAT. We also required that antibiotics had to be prescribed for at least 24 hours. All other regimens were
classified as non-IAAT. Prior antibiotic exposure was any
exposure to an antibiotic within the preceding 90 days.
Combination antimicrobial treatment was not required
for IAAT designation. This is supported by multiple studies indicating that while dual therapy is more likely than
single therapy to result in appropriate coverage, it is not
necessarily associated with better outcomes provided the
organism is adequately covered by a single drug [18]. We
utilized the same time frame (90 days prior to the onset of
the current episode of bacteremia) to define prior hospitalization. In contrast, prior bacteremia was defined by a
bacteremia that had occurred within 30 days of the current
episode. Multidrug-resistant P. aeruginosa (MDR-PA) was
defined as P. aeruginosa resistant to at least three of the
following classes of antimicrobials: aminoglycosides,
anti-pseudomonal penicillins, anti-pseudomonal cephalosporins, carbapenems, and fluoroquinolones. A case
was classified as MDR if the blood culture was positive
for a MDR-PA, an ESBL organism, or a CPE. Both ESBL
and CPE status were established based on molecular
laboratory testing.
Antimicrobial treatment algorithms

From January 2002 through to the present, Barnes-Jewish
Hospital utilized an antibiotic control program to help
guide antimicrobial therapy. During this time cefepime,
gentamicin, vancomycin, or fluconazole use was unrestricted. However, initiation of ciprofloxacin, imipenem,
meropenem, piperacillin/tazobactam, linezolid, daptomycin, or micafungin was restricted and required preauthorization from a clinical pharmacist or infectious diseases
physician. Each ICU had a clinical pharmacist who reviewed antibiotic orders to ensure that dosing and the
interval of administration were adequate for patients
based on body size, renal function, and resuscitation status. After daytime hours the on-call clinical pharmacist
reviewed and approved the antibiotic orders. The initial
antibiotic dosages employed for treatment were as follows:
cefepime, 1 to 2 g every 8 hours; piperacillin-tazobactam,
4.5 g every 6 hours; imipenem, 0.5 g every 6 hours; meropenem, 1 g every 8 hours; ciprofloxacin, 400 mg every 8
hours; gentamicin, 5 mg/kg once daily; vancomycin, 15
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mg/kg every 12 hours; linezolid, 600 mg every 12 hours;
daptomycin, 6 mg/kg every 24 hours; fluconazole, 800 mg
on the first day followed by 400 mg daily; and micafungin,
100 mg daily.
Starting in June 2005, with regular updates, a sepsis
order set was implemented in the emergency department,
general wards, and the ICUs with the intent of standardizing empiric antibiotic selection for patients with sepsis
based on the infection type (i.e. community-acquired pneumonia, healthcare-associated pneumonia, intra-abdominal
infection, and so forth) and the hospital’s antibiogram.
However, antimicrobial selection, dosing, and de-escalation
of therapy were still optimized by clinical pharmacists in
these clinical areas.
Antimicrobial susceptibility testing

The microbiology laboratory performed antimicrobial susceptibility of the Gram-negative blood isolates using the
disk diffusion method according to guidelines and breakpoints established by the Clinical Laboratory and Standards
Institute and published during the inclusive years of the
study [19,20].
Data elements

Patient-specific baseline characteristics and process of care
variables were collected from the automated hospital
medical record, microbiology database, and pharmacy
database of Barnes-Jewish Hospital. Electronic inpatient
and outpatient medical records available for all patients in
the BJC Healthcare system were reviewed to determine
prior antibiotic exposure. The baseline characteristics
collected included: age, gender, race, past history of congestive heart failure, chronic obstructive pulmonary disease, diabetes mellitus, chronic liver disease, underlying
malignancy, and end-stage renal disease requiring dialysis.
The comorbidities were identified based on their corresponding ICD-9-CM codes. The Acute Physiology and
Chronic Health Evaluation II and Charlson comorbidity
scores were calculated based on clinical data present during the 24 hours after the positive blood cultures were
obtained [21]. This was done to accommodate patients
with community-acquired and healthcare-associated
community-onset infections who only had clinical data
available after blood cultures were drawn. Healthcareassociated infections were defined by the presence of at
least one of the following risk factors: recent hospitalization (within 90 days of the current one); immune suppression; nursing home residence; hemodialysis; and prior
antibiotics (within 90 days of the current hospitalization).
The primary outcome variable was hospital mortality.
Because we were interested in understanding the contribution of MDR pathogens to the risk of receiving nonIAAT, we examined this variable as a secondary endpoint
in a logistic regression.
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Statistical analyses

Continuous variables were reported as means with standard deviations and as medians with 25th and 75th percentiles. Differences between mean values were tested via
the Student’s t test, while those between medians were
examined using the Mann–Whitney U test. Categorical
data were summarized as proportions, and the chi-square
test or Fisher’s exact test for small samples was used to
examine differences between groups. We developed several multiple logistic regression models to identify clinical
risk factors that were associated with hospital mortality.
In the mortality models, all risk factors that were significant at ≤0.20 in the univariate analyses, as well as
all biologically plausible factors even if they did not
reach this level of significance, were included in the
corresponding multivariable analyses. All variables entered into the models were examined to assess for colinearity, and interaction terms were tested. The most
parsimonious models were derived using the backward manual elimination method, and the best-fitting
model was chosen based on the area under the receiver
operating characteristics curve (c statistic). The model’s
calibration was assessed with the Hosmer–Lemeshow
goodness-of-fit test. Similarly, the most parsimonious
model for the predictors of inappropriate empiric antibiotic was computed and its fit was tested with the c statistic and the Hosmer–Lemeshow goodness of fit. All tests
were two tailed, and P <0.05 was deemed a priori to represent statistical significance.
All computations were performed in Stata/SE, version 9
(StataCorp, College Station, TX, USA).

Results
In total, 1,076 patients with severe sepsis or septic shock
due to a Gram-negative pathogen met the inclusion
criteria. The distribution of the pathogens is presented in
Table 1. Among these 1,076 culture-positive cases, there
were 63 (5.9%) cultures that met the MDR criteria (Table 1).
The most common MDR organism was MDR-PA, accounting for 15.0% of all P. aeruginosa isolates.
Among the 1,064 patients whose hospital disposition
was known, 311 (29.2%) died in the hospital. Their baseline characteristics are presented in Table 2. Patients
who died were older, less likely to be admitted from
home, and had a higher comorbidity burden than those
who survived their hospitalization, as signified by the
Charlson comorbidity score. A higher proportion of those
patients who died prior to discharge (95.7%) had a risk
factor for a healthcare-associated infection than those
who were discharged alive (91.4%, P = 0.014).
In the run-up to and at the time of sepsis onset, patients who did not survive had a slightly longer presepsis
hospital length of stay, although this difference did not
meet the predetermined level of statistical significance
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Table 1 Microbiology of Gram-negative severe sepsis and septic shock
All organisms

MDR-PA

N

%

N

%

N

ESBL
%

N

CP
%

Total MDR

Pseudomonas aeruginosaa

173

16.08

26

15.03

1

0.58

1

0.58

Acinetobacter spp.b

73

6.78

1

1.37

1

1.37

Bacteroides spp.

83

7.71

Stenotrophomonas maltophilia

22

2.04

Klebsiella pneumoniaec

217

20.17

13

5.99

8

3.69

Escherichia coli

284

26.39

14

4.93

Klebsiella oxytoca

35

3.25

3

8.57

Proteus mirabilis

55

5.11

Serratia marcescens

46

4.28

Citrobacter freundii

25

2.32

Enterobacter aerogenes

35

3.25

Enterobacter cloacae

90

8.36

1

1.11

Other

6

0.56

Polymicrobial

191

17.75

Total

1,076

100.00

N

%

63f

5.86

Enterobacteriaceae

d

26

33e

10
a

CP, carbapenemase-producing; ESBL, extended-spectrum beta lactamase; MDR, multidrug resistant; MDR-PA, multidrug resistant P. aeruginosa. Same MDR-PA
specimen that was positive for both ESBL and CP. bSame Acinetobacter baumanii specimen that was positive for both ESBL and CP. cTwo patients each had one
CP K. pneumoniae + one ESBL K. pneumoniae. dAeromonas sobria (n = 2), Haemophilis influenza (n = 2), Pseudomonas putida (n = 1), Achromobacter sp. (n = 1). eThese
33 specimens came from 32 patients (one patient had 2 ESBL organisms: E. coli and K. pneumoniae). fThe six-sample discrepancy is explained by the above overlaps,
and one patient has ESBL E. coli and CP K. pneumoniae.

(Table 2). Several healthcare-associated factors (hemodialysis, prior hospitalization, and antibiotics) were more
prevalent among nonsurvivors. However, the vast majority of the cohort (over 90%) had at least one healthcareassociated risk factor (Table 2). Additionally, survivors
had a higher frequency of having had surgery during the
index hospitalization than those who died. All markers
of severity of acute illness were higher in patients who
died compared with those who survived; the Acute
Physiology and Chronic Health Evaluation II score was
higher, and septic shock and the need for mechanical
ventilation were significantly more prevalent among
nonsurvivors than among survivors (Table 2, Figure 1).
Urine and an infected line were less likely sources of infection and the lung was more likely as a source of infection among nonsurvivors compared with survivors.
There were also striking differences between the two
groups in terms of the likelihood of a MDR pathogen
as the sepsis culprit (10.0% among nonsurvivors vs.
4.0% among survivors, P <0.001) (Figure 1). Additionally,
nonsurvivors were approximately three times more likely
to receive non-IAAT than those patients who survived
their hospitalization (43.4% vs. 14.6%, P <0.001) (Figure 1).
Among the 245 patients who received non-IAAT, resistance to instituted empiric therapy was far more prevalent
as a reason (75.5%) than delay in treatment (24.5%). When
stratified by hospital death, the relationship generally held,

although delay in treatment was slightly more likely
among those who died (28.9%) than those who survived
their hospitalization (19.1%, P = 0.076). Similarly, delay in
therapy accounted for a minority of non-IAAT among patients with a MDR pathogen (25.5%), with a nearly identical frequency of delay observed among those without a
MDR pathogen (23.8%, P = 0.798).
Multiple logistic regression models were constructed
and tested for fit, with the factors presented in Table 3
having the best discrimination. In this model, as in others
that included this model, receiving non-IAAT was the
strongest predictor of hospital death with an adjusted
odds ratio of 3.87 (95% confidence interval = 2.77 to 5.41,
P <0.001, c statistic = 0.777).
When focusing on the choice of empiric treatment
among patients with a MDR pathogen versus those without, the unadjusted odds ratio of receiving non-IAAT was
11.79 (95% confidence interval = 6.55 to 21.23, P <0.001).
In a logistic regression model to examine the factors that
contribute to this inappropriate choice of therapy, a MDR
pathogen as the etiology of sepsis was the strongest predictor of inappropriate treatment with an adjusted odds
ratio of 13.05 (95% confidence interval = 7.00 to 24.31,
P < 0.001, c statistic = 0.738) (Table 4). This parameter
had by far the highest odds of any variable retained in the
model of predictors of non-IAAT. (Tables 5, 6 and 7 present
the details of characteristics based on appropriateness of
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Table 2 Baseline and infection characteristics and outcomes
Died (n = 311)
N

P value

Survived (n = 753)
%

N

%

Baseline characteristics
Age (years)
Mean ± standard deviation

65.0 ± 13.0

62.3 ± 14.8

Median (25th, 75th percentiles)

66.5 (55, 73.5)

63 (53, 72)

0.036

0.101

Race
Caucasian

198

63.67

504

66.93

African-American

96

30.87

193

25.63

Hispanic

0

0.00

1

0.13

Other

1

0.32

8

1.06

Unknown

10

3.22

41

5.44

Asian

6

1.93

6

0.80

140

45.60

356

47.34

0.518

Home

178

57.23

530

70.48

0.001

Nursing home/LTAC

30

9.65

62

8.24

Sex, female
Admission source

Transfer from other hospital

88

28.30

143

19.02

Unknown

14

4.50

14

1.86

Other

1

0.13

3

0.40

CHF

78

25.08

136

18.06

0.009

COPD

92

29.58

171

22.71

0.018

CLD

65

20.90

105

13.94

0.005

DM

79

25.40

195

25.90

0.867

CKD

68

21.86

126

16.73

0.049

Malignancy

128

41.16

340

45.15

0.232

HIV

6

1.93

6

0.80

0.112

Comorbidities

Charlson comorbidity score
Mean ± standard deviation

5.4 ± 3.6

4.9 ± 3.3

Median (25th, 75th percentiles)

5 (3, 8)

4 (2, 7)

0.022

HCA risk factors

292

95.74

676

91.35

0.014

Hemodialysis

41

13.62

52

6.92

0.001

Immune suppression

134

44.08

290

39.30

0.153

Prior hospitalization

204

69.86

445

62.06

0.019

Nursing home residence

30

9.65

62

8.23

0.456

Prior antibiotics

194

62.38

405

53.78

0.010

Hospital-acquired BSI

153

49.20

350

46.48

0.420

Bacteremia that was not HCA (that is, community acquired)

19

6.11

77

10.23

0.033

Prior bacteremia within 30 days

37

11.90

97

12.88

0.660

a

Sepsis characteristics and outcomes
LOS prior to sepsis onset, days
Mean ± standard deviation

9.8 ± 18.4

7.3 ± 12.1

Median (25th, 75th percentiles)

2 (0, 13)

1 (0, 11)

0.227
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Table 2 Baseline and infection characteristics and outcomes (Continued)
Surgery
None

227

73.94

510

68.36

Abdominal

38

12.38

150

20.11

Extra-abdominal

42

13.68

86

11.53

Central line
Total parenteral nutrition

0.011

199

67.46

462

63.55

0.236

19

6.33

56

7.53

0.499

APACHE II score
Mean ± standard deviation

19.9 ± 7.4

15.8 ± 5.4

Median (25th, 75th percentiles)

19 (15, 25)

16 (12, 19)

Mean ± standard deviation

21.6 ± 18.7

22.6 ± 17.7

Median (25th, 75th percentiles)

16.4 (7.2, 32)

18.0 (8.2, 37)

<0.001

Peak WBC

0.275

b

Infection source
Urine

60

19.29

201

26.69

0.011

Abdomen

49

15.76

106

14.08

0.48

Lung

88

28.30

129

17.13

<0.001

Line

23

7.40

86

11.42

0.049

CNS

4

1.29

3

0.40

0.204

Skin

20

6.43

42

5.58

0.589

Unknown

90

28.94

241

32.01

0.326

Polymicrobal

60

19.29

129

17.13

0.402

Total hospital LOS (days)
Mean ± standard deviation

22.9 ± 28.3

23.3 ± 23.7

Median (25th, 75th percentiles)

15 (6, 28)

17 (8, 30)

Mean ± standard deviation

13.1 ± 19.8

16.0 ± 18.0

Median (25, 75)

8 (3, 17)

10 (6, 20)

0.013

Hospital LOS following sepsis onset, days

<0.001

APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; CHF, congestive heart failure; CKD, chronic kidney disease; CNS, central
nervous system; COPD, chronic obstructive pulmonary disease; CLD, chronic liver disease; DM, diabetes mellitus; HCA, healthcare-associated; LOS, length of stay;
LTAC, long-term acute care; WBC, white blood cells. aHospital-acquired BSI defined as BSI that developed after day 2 of hospitalization. bMultiple sources possible.

treatment, as well as an alternative model for the predictors of non-IAAT. See Table 7 footnote for a brief
discussion of that model.)

Discussion
This large retrospective analysis confirms that non-IAAT
is a key determinant of short-term mortality among
patients with severe sepsis and septic shock due to a
Gram-negative organism. More importantly, our findings
indicate that the presence of a MDR Gram-negative pathogen is strongly associated with non-IAAT. Despite the
relatively low prevalence of a MDR phenotype among all
subjects with Gram-negative bacteremia, these pathogens exert an excessive impact on mortality. In other
words, MDR pathogens disproportionately affect outcomes
through an intermediate step as it relates to antibiotic therapy. In light of the increasing frequency of multidrug
resistance, our observations suggest that urgent action is

needed to prevent potential escalation of mortality rates in
severe sepsis and septic shock.
Because the co-occurrence of MDR pathogens and
non-IAAT was relatively rare, it is important to consider
the context of total non-IAAT exposure. The pool for
the MDR pathogens as defined in our study comprises the
vast majority of Gram-negative organisms responsible for
serious infections in the ICU. That is, compared with
Acinetobacter spp., for example, the relative prevalence of
P. aeruginosa and Enterobacteriaceae was an order of magnitude higher. Epidemiologically, this imbalance makes it
imperative for clinicians to consider these organisms first
and foremost when choosing empiric treatment. We have
demonstrated that multidrug resistance among these
organisms comprises one important mechanism for errors
in empiric coverage. At the same time, Acinetobacter spp.
and Stenotrophomonas maltophilia infections, although
a minority, were extremely likely to be subject to
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Died

Survived

100%
90%
80%
70%
60%
50%
40%
30%

20%
10%
0%
Severe sepsis

Pressors

Mechanical
ventilation

MDR

Non-IAAT

Figure 1 Sepsis severity, resistance and initial treatment. IAAT, initially appropriate antibiotic therapy; MDR, multidrug resistant. P <0.001 for
each comparison.

inappropriate empiric treatment (Table 6). Because
the risk for drug resistance is very high among these
organisms, the observed elevated rates of non-IAAT
are probably not because the clinician did not consider
their risk for resistance, but rather due to his/her determination that these were not likely pathogens. This approach therefore represents a slightly different mechanism
Table 3 Predictors of hospital mortalitya
Odds ratio 95% confidence P value
interval

for causing non-IAAT and implies a different solution.
Rather than understanding the antibiogram of common
pathogens, this requires a clinician to be aware of the rates
of specific less common organisms at his/her institution.
An additional important mechanism for receiving nonIAAT exists based on the timing of empiric therapy.
Fully one-quarter of all non-IAAT fell into this category
when there was no evidence of empiric treatment within
Table 4 Predictors of receiving initially inappropriate
antibiotic therapya

Non-IAAT

3.872

2.770 to 5.413

<0.001

Chronic liver disease

1.942

1.319 to 2.860

0.001

Septic shock

1.846

1.335 to 2.553

<0.001

Multidrug resistant

13.05

7.00-24.31

<0.001

Pneumonia

1.766

1.237 to 2.522

0.002

HIV

3.64

1.02-12.95

0.046

Mechanical ventilation

1.669

1.172 to 2.376

0.005

2.00-4.08

<0.001

1.076

1.047 to 1.105

<0.001

Transferred from another
hospital

2.86

APACHE II score (per 1 point)
Surgery

0.701

0.560 to 0.879

0.002

Nursing home resident

2.28

1.35-3.84

0.002

Admitted from home

0.677

0.489 to 0.936

0.018

Prior antibiotics

2.06

1.47-2.87

<0.001

0.034

Polymicrobial

1.90

1.30-2.77

0.001

Congestive heart failure

1.61

1.11-2.35

0.013

APACHE II score (per 1 point)

1.05

1.02-1.07

<0.001

Urosepsis

0.675

0.469 to 0.972

a
Independent variables included but not retained in the model at alpha ≤0.05:
age, race, admission sources other than home (nursing home or transfer from
another facility), comorbidities of congestive heart failure, chronic obstructive
pulmonary disease, chronic kidney disease and human immune deficiency
virus infection, Charlson comorbidity score, healthcare-associated infection risk
factors (hemodialysis, immune suppression, prior hospitalization, prior antibiotics),
mechanical ventilation, and infection source other than urine (lung, abdomen,
line, central nervous system, skin). Variables pressors and severe sepsis were
excluded because of collinearity with septic shock. APACHE, Acute Physiology
and Chronic Health Evaluation; IAAT, initially appropriate antibiotic therapy. Area
under the receiver operating characteristics curve = 0.777; Hosmer–Lemeshow
P = 0.823.

Odds ratio 95% confidence P value
interval

a
Independent variables included but not retained in the model at alpha ≤0.05:
age, admission source other than transfer from another hospital (home or
nursing home), comorbidities of chronic obstructive pulmonary disease, chronic
kidney disease, diabetes and malignancy, healthcare-associated infection risk
factors hemodialysis, immune suppression and prior hospitalization, prior
bacteremia, hospital length of stay prior to the onset of bacteremia, surgery,
central line, total parenteral nutrition, septic shock, and infection source. APACHE,
Acute Physiology and Chronic Health Evaluation. Area under the receiver
operating characteristics curve = 0.738, Hosmer–Lemeshow P = 0.664.
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Table 5 Baseline and infection characteristics
IAAT

P value

Non-IAAT

N

%

N

%

819

76.97

245

23.03

Baseline characteristics
Age (years)
Mean ± standard deviation

60.3 ± 15.1

61.8 ± 15.1

Median (25th, 75th percentile)

62 (51, 71)

63 (52, 72)

0.165

Race
Caucasian

543

66.30

159

64.90

0.643

African-American

218

26.62

71

28.98

Hispanic

1

0.12

0

0.00

Other

9

1.10

0

0.00

Unknown

39

4.76

12

4.90

Asian

9

1.10

3

1.22

377

46.14

119

48.57

0.504

Home

585

71.52

123

50.20

<0.001

Nursing home (including LTAC)

62

7.58

30

12.24

Transfer from other hospital

148

18.09

83

33.88

Unknown

20

2.44

8

3.27

Other

3

36.00

1

0.41

CHF

150

18.32

64

26.12

0.009

COPD

190

23.30

73

29.80

0.043

CLD

134

16.36

36

14.69

0.619

DM

202

24.66

72

29.39

0.157

CKD

141

17.22

53

21.63

0.131

Malignancy

379

46.28

89

36.33

0.007

HIV

7

85.00

5

2.04

0.161

Sex, female
Admission source

Comorbidities

Charlson comorbidity score
Mean ± standard deviation

5.00 ± 3.35

5.18 ± 3.52

Median (25th, 75th percentile)

5 (2, 7)

4 (3, 8)

0.624

HCA risk factor
Hemodialysis

55

6.80

38

15.64

<0.001

Immune suppression

334

41.70

90

37.34

0.228

Prior hospitalization

485

62.26

164

71.30

0.012

Nursing home residence

62

7.57

30

12.24

0.022

Prior antibiotics

429

52.38

170

69.39

<0.001

Hospital-acquired BSIa

366

44.69

137

55.92

0.002

Prior bacteremia within 30 days

95

11.60

39

15.92

0.074

Sepsis characteristics
LOS prior to bacteremia (days)
Mean ± standard deviation

7.0 ± 12.1

11.7 ± 19.6

Median (25th, 75th percentile)

1 (0, 10)

5 (0, 16)

<0.001
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Table 5 Baseline and infection characteristics (Continued)
Surgery
None

575

70.90

162

66.94

Abdominal

152

18.74

36

14.88

Extra-abdominal

84

10.36

44

18.18

Central line
TPN at time of bacteremia or prior to it during index hospitalization

0.033

491

62.31

170

72.34

0.005

53

6.59

22

9.17

0.175

APACHE II score
Mean ± standard deviation

16.5 ± 6.2

Median (25th, 75th percentile)

16 (12, 20)

Severe sepsis

451

18.7 ± 6.6
18 (14, 22)
55.07

108

<0.001
44.08

Septic shock requiring pressors

368

44.93

137

55.92

On mechanical ventilation

176

21.57

89

36.33

0.003

<0.001

Peak WBC
Mean ± standard deviation

22.1 ± 18.3

22.9 ± 17.1

Median (25th, 75th percentile)

17.0 (7.5, 33.8)

18.3 (8.6, 37.0)

0.298

Infection sourceb
Urine

206

25.15

55

22.45

0.446

Abdomen

124

15.14

31

12.65

0.355

Lung

154

18.80

63

25.71

0.024

Line

87

10.62

22

8.98

0.548

CNS

6

0.73

1

0.41

1.000

Skin

41

5.01

21

8.57

0.043

Unknown

260

31.75

71

29.98

0.432

Polymicrobal BSI

130

15.87

59

24.08

0.003

MDR BSI

16

1.95

45

18.37

<0.001

a

Hospital-acquired BSI defined as BSI that developed after day 2 of hospitalization. bMultiple sources possible. APACHE, Acute Physiology and Chronic Health
Evaluation; BSI, bloodstream infection; CHF, congestive heart failure; CKD, chronic kidney disease; CLD, chronic liver disease; CNS, central nervous system; COPD,
chronic obstructive pulmonary disease; DM, diabetes mellitus; HCA, healthcare-associated; IAAT, initially appropriate antibiotic therapy; LOS, length of stay; LTAC,
long-term acute care; MDR, multidrug resistant; TPN, total parenteral nutrition; WBC, white blood cells.

24 hours of obtaining the blood culture. This informs
yet another corrective approach, one that requires simply to recognize the presence of a severe infection and
to institute empiric treatment in a timely manner. These
three mechanisms for exposure to non-IAAT and their
corrective strategies are subtly yet importantly different
from one another. In the current study we focus specifically on the impact of multidrug resistance on the risk
of non-IAAT.
The prevalence of Gram-negative resistance has been
mounting over the last decade [4-6]. However, most
prior work describing the epidemiology of MDR Gramnegative pathogens has focused on the prevalence of
resistance among specific species in specific infections.
For example, a recent study demonstrated that between
2000 and 2009 nationwide in the United States there
was a rise of MDR-PA from 10.7 to 13.5% in bloodstream infections, and from 19.2 to 21.7% in pneumonia
[4]. The proportion of P. aeruginosa that met the MDR

definition in the current study (15.0%) is consistent with
these national estimates. The prevalence of carbapenemresistant Enterobacteriaceae that we report here is also
in line with national estimates [4-6]. In general, the similarity of the overall prevalence of multidrug resistance in
our study to what has been reported nationally lends
external validity to our observations. Moreover, our study
is unique in its pragmatic perspective relevant to an ICU
clinician and focuses on a common syndrome that represents a final common pathway for several infection types.
Much research from the last decade has highlighted the
strong relationship between the choice of empiric antimicrobial treatment and the risk of death among patients
hospitalized with serious infections. Most studies suggest
that the risk of hospital death in association with nonIAAT goes up twofold to fourfold when compared with
patients who receive appropriate coverage [7-9,11-15].
Furthermore, switching from inappropriate to appropriate
coverage once the culture results have become available
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Table 6 Distribution of inappropriate treatment by
organism
IAAT

Non-IAAT

N

%

N

%

819

76.97

245

23.03

Pseudomonas aeruginosa

129

75.44

42

24.56

Acinetobacter spp.

19

26.03

54

73.97

Bacteroides spp.

51

63.75

29

36.25

Stenotrophomonas maltophilia

2

9.09

20

90.91

Klebsiella pneumoniae

186

86.92

28

13.08

Escherichia coli

247

88.21

33

11.79

Klebsiella oxytoca

27

77.14

8

22.86

Proteus mirabilis

45

81.82

10

18.18

Serratia marcescens

39

84.78

7

15.22

Citrobacter freundii

22

88.00

3

12.00

Enterobacter aerogenes

29

82.86

6

17.14

Enterobacter cloacae

72

80.90

17

19.10

Polymicrobial

130

68.78

59

31.22

Enterobacteriaceae

IAAT, initially appropriate antibiotic therapy.

Table 7 Predictors of receiving initially inappropriate
antibiotic therapya
Odds ratio 95% confidence P value
interval
Stenotrophomonas maltophilia 91.981

20.538 to 411.956 <0.001

Multidrug resistant

23.045

12.097 to 43.900

<0.001

Acinetobacter spp.

17.410

9.600 to 31.574

<0.001

HIV

4.547

1.255 to 16.477

0.021

Bacteroides spp.

4.202

2.466 to 7.159

<0.001

Transfer from another hospital 2.280

1.527 to 3.403

<0.001

Polymicrobial

2.294

1.498 to 3.512

<0.001

Prior antibiotics

1.793

1.238 to 2.597

0.002

Congestive heart failure

1.683

1.097 to 2.582

0.017

APACHE II score

1.051

1.023 to 1.081

<0.001

a

This model includes all factors identified in the model in Table 4 with the
addition of the three pathogens with strikingly different initially appropriate
antibiotic therapy patterns identified in Table 6. Please note that all other
previously identified factors stayed in, except nursing home residence, which
fell out based on significance (lower bound of the 95% confidence interval
was 0.921). The area under the receiver operating characteristics curve is
improved compared with the model in Table 4. However, we feel that this
model does not add any clinical or policy utility when compared with the
original model. While the multidrug-resistant designation provides an
actionable data point with regard to stewardship and prevention of resistance
development, the other microbiology variables simply represent organisms
routinely isolated from septic patients. For this reason, we are offering this
alternate regression and retaining the original regression as a part of the main
manuscript. These data further emphasize the need for clinicians to know their
individual centers’ case mix vis-à-vis microorganisms associated with sepsis
and their predominant susceptibility patterns. APACHE, Acute Physiology and
Chronic Health Evaluation. Area under the receiver operating characteristics
curve = 0.827, Hosmer–Lemeshow P = 0.162.

does not reduce the mortality risk imparted by this early
failure [10]. In this way our study adds to the understanding of the importance of choosing appropriate empiric
treatment specifically to the outcomes of Gram-negative
sepsis, and extends this understanding to suggest not only
the mechanism for this finding, but also the contribution
of multidrug resistance to the risk of making this important error in early management.
The potential policy and public health implications of
our results are significant. Most attempts to improve
rates of IAAT have relied on a strategy of prompt administration of broad empiric coverage informed by the local
antibiogram, followed by de-escalation. In fact, this is the
strategy advocated by the Surviving Sepsis Campaign [16].
To prevent antibiotic abuse, the broad regimen is tailored
as culture data become available, and the shortest appropriate course of therapy is given. This paradigm suggests
that the way to address low rates of IAAT is to shift to
using broader spectrum agents such as anti-pseudomonal
carbapenems or ESBLs and/or chephalosporins. Unfortunately, in the case of MDR Gram-negative organisms, this
is simply not an option. Few agents currently available
provide in vitro activity against MDR-PA and CPE. Those
agents that are available, such as colistin, carry important,
albeit somewhat controversial, safety concerns [22-25].
Simply selecting broader spectrum agents for the initial
therapy is therefore not an option, because the current
antibiotic armamentarium does not cover these MDR
organisms. This highlights why new agents are urgently
needed. As such, regulatory authorities and policy-makers
need to develop expedited pathways for antibiotic development and approval. Such initiatives in the United States
as the Generating Antibiotic Incentives Now Act, which
provide incentives to support the development of newer
antibiotics, are to be lauded [26]. These efforts must
continue to be expanded and refined.
An additional point worth emphasizing is the relatively
low prevalence of MDR pathogens in our study, and the
implications of this for potential overuse of empiric
broad-spectrum antibiotics, if such are available. Although certainly suboptimal with respect to both overuse and increased resource utilization, at the moment
there is no way to tailor such therapies with any degree
of precision. Yet not administering appropriate coverage
results in a high penalty for the patient who is unlucky
enough to harbor a MDR organism, with a fourfold increase in the risk of death. This situation underscores
the urgency of the need for development of faster diagnostic tools, as well as risk stratification algorithms that
may help clinicians to use broad-spectrum drugs appropriately. At the moment, however, the only viable
solution appears to be to understand local resistance
patterns in real time and make therapeutic choices based
on them.
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Our study has a number of limitations. As a retrospective
cohort it is prone to several forms of bias, most notably
selection bias. We attempted to mitigate this by enrolling
consecutive patients fitting the pre-determined enrollment
criteria. Although we dealt with confounders by adjusting
for those that were available, it is possible that some residual confounding remains. One specific potential residual
confounder is the type of surgery; that is, although we have
data on whether each patient either had a surgical procedure or was cared for on a surgical service during his/her
hospitalization, we do not know whether the surgery was
related to the sepsis episode or was performed for infectious source control. However, based on prior experience
at BJC, only a minority of patients is likely to have undergone source control surgery. The fact that this is a singlecenter study in a very specific population of patients (those
with Gram-negative sepsis) may diminish the generalizability of our results to other centers and populations.
One important point is that Clinical Laboratory and
Standards Institute break-points for susceptibility changed
for some of the antibiotics during the study time frame
[19,20]. The lowering of these values almost certainly
resulted in an increase in the proportion of resistant organisms. This likely increase, however, would dilute rather
than inflate the impact of multidrug resistance on the receipt of IAAT. Since we used only the susceptibility profile
and the timing of antibiotic administration as surrogates
for IAAT, our definition may have been overly liberal and
included some cases that would have been deemed nonIAAT if other factors such as dosing and tissue penetration
had been examined. Another source of possible misclassification is our use of ICD-9-CM codes to identify organ
failures. While this identification may be less accurate than
clinical data, this methodology has been validated and
widely utilized in health services research [17]. The same
situation arose for comorbidities, thus eliminating the possibility of examining whether or how their severity may impact the outcomes. Finally, because we examined hospital
mortality rather than the more standard 28-day mortality
as the primary outcome for our study, we may have underestimated the magnitude of this outcome.

Conclusions
In summary, our study provides evidence that once the
high risk of a serious infection has been recognized by a
clinician and empiric treatment for common pathogens
instituted, MDR organisms are an important factor in
determining the risk of non-IAAT, and, by extension,
hospital mortality in Gram-negative sepsis. Given the
paucity of currently available antimicrobial options to
cover this emerging threat, the key immediate solution
is their prevention through various protocols to address
ventilator and central venous catheter care, as well as
through antibiotic stewardship programs [27-29].
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Definitions
 Septic shock: vasopressors (norepinephrine,











dopamine, epinephrine, phenylephrine, or
vasopressin) initiated within 24 hours of the blood
culture collection date and time.
IAAT: initially prescribed antibiotic regimen active
against the identified pathogen based on in vitro
susceptibility testing and administered within
24 hours following blood culture collection.
Prior antibiotic exposure: any exposure to an
antibiotic within the preceding 90 days.
Prior hospitalization: any hospitalization within the
preceding 90 days.
Prior bacteremia: a bacteremia episode within
30 days of the current episode.
MDR-PA: a P. aeruginosa resistant to at least three
of the following classes of antimicrobials:
aminoglycosides, anti-pseudomonal penicillins,
anti-pseudomonal cephalosporins, carbapenems,
and fluoroquinolones.
MDR case: blood culture positive for a MDR-PA,
an ESBL organism or a CPE.
Healthcare-associated infection: the presence of at
least one of the following risk factors: recent
hospitalization (within 90 days of the current one);
immune suppression; nursing home residence;
hemodialysis; and prior antibiotics (within 90 days
of the current hospitalization).

Key messages
 Among patients with severe sepsis/septic shock due

to a Gram-negative organism, initially inappropriate
antibiotic treatment is associated with a threefold
increase in hospital mortality.
 Multidrug resistance is strongly associated with
inappropriate treatment.
Abbreviations
CPE: carbapenemase-producing Enterobacteriaceae; ESBL: extended-spectrum
beta-lactamase; IAAT: initial appropriate antibiotic therapy; ICD-9CM: International Classification of Diseases, Version 9, Clinical Modification;
MDR: multidrug resistant; MDR-PA: multidrug-resistant Pseudomonas aeruginosa.
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